bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, has just launched VIDAS® C. difficile Toxin A&B, a test for the detection of a bacterium responsible for fatal nosocomial epidemics in Canada, the United States and, more recently, in Europe. With results in just 75 minutes (as opposed to 24 to 48 hours using the reference method), this test enables faster therapeutic decision-making and patient isolation measures in order to prevent all types of transmission. Performing this test on the VIDAS® system provides laboratories with the first fully automated and standardized solution. Finally, by combining the detection of both A and B toxins, VIDAS® C. difficile Toxin A&B significantly increases detection sensitivity and reliability.
